Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Venture Financing 17
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
Private Equity 19
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Partnerships 20
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20
Replimune Enters into Co-Development Agreement with Regeneron Pharma 22
Regeneron Pharma Enters into Agreement with Alnylam Pharma 23
Regeneron Pharma and ISA Pharma Enter into Partnership 24
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28
Inovio Pharma and Regeneron Pharma Enter into Agreement 29
Indivumed Enters into Agreement with Regeneron Pharma 30
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34
Bayer Enters into Co-Development Agreement with Regeneron Pharma 35
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37
Regeneron Pharma Enters into Development Agreement with BARDA 38
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Amends Co-Development Agreement with Sanofi 41
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44
Licensing Agreements 46
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48
Regeneron Pharma Enters into Licensing Agreement with MedImmune 50
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52
Regeneron Pharmaceuticals Inc – Key Competitors 53
Regeneron Pharmaceuticals Inc – Key Employees 54
Regeneron Pharmaceuticals Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Nov 06, 2018: Regeneron reports third quarter 2018 financial and operating results 57
Aug 02, 2018: Regeneron reports second quarter 2018 financial and operating results 59
May 03, 2018: Regeneron Reports First Quarter 2018 Financial And Operating Results 62
Feb 08, 2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results 65
Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results 68
Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results 71
May 04, 2017: Regeneron Reports First Quarter 2017 Financial And Operating Results 74
Feb 09, 2017: Regeneron Reports Fourth Quarter And Full Year 2016 Financial And Operating Results 77
Corporate Communications 81
Jun 23, 2018: Regeneron Announces Departure of Michael Aberman, M.D., Senior Vice President of Strategy and Investor Relations 81
Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial 82
Jan 31, 2017: Tony Coles, M.D., Elected To Regeneron Board Of Directors 83
Legal and Regulatory 84
Mar 19, 2018: Regeneron Pharmaceuticals Announce Regarding Novartis Complaint on ‘688 Patent 84
Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron’s Petition to Rehear the Panel’s Decision Affirming Merus’ Inequitable Conduct Claim Against Regeneron 85
Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron 86
Government and Public Interest 87
Aug 07, 2018: Regeneron: Statement regarding new CMS guidance for part B drugs 87
Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease 88
Mar 13, 2018: Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease 90
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World’s Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis 92
Product News 94
10/03/2018: Onco360 selected as the exclusive specialty pharmacy for libtayo (cemiplimab-rwlc) limited distribution pharmacy network 94
09/28/2018: FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma 95
09/08/2017: Sanofi and Regeneron Announce That Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma 97
08/23/2018: Intellia Therapeutics presents progress in lead in vivo program at cold spring harbor laboratory’s fourth meeting on genome engineering: the CRISPR-Cas revolution 98
08/17/2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis 99
05/31/2018: Regeneron’s Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak 100
04/25/2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 101
02/08/2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 102
01/13/2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 103
Product Approvals 104
Apr 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 104
Apr 03, 2018: EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma 105
Clinical Trials 106
Oct 08, 2018: Libtayo (Cemiplimab-RWLC) data at ESMO 2018 congress provide new insights in six tumor types under investigation 106
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints 108
Jun 04, 2018: New England Journal of Medicine Publishes pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma 109
May 16, 2018: Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO 111
Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology 112
Dec 13, 2017: Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma 113
Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program 114
Nov 07, 2017: Regeneron and Sanofi to Present New Analyses from the Praluent (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 115
Nov 01, 2017: Regeneron to Share Clinical Progress of Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting 117
Nov 01, 2017: Regeneron to Share Clinical Progress of REGN1979 in B-Cell Lymphomas at the 2017 ASH Annual Meeting 118
Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 119
Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 121
Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 123
Jun 04, 2017: Regeneron And Sanofi Present Positive Study Results For Investigational PD-1 Antibody REGN2810 At American Society Of Clinical Oncology (Asco) Annual Meeting 125
Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 126
Other Significant Developments 128
Sep 11, 2018: Governor Cuomo announces Regeneron to create 1,500 biotech jobs in major New York expansion 128
Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 130
May 18, 2018: Experimental MERS Treatments Enter Clinical Trial 131
Appendix 132
Methodology 132
About GlobalData 132
Contact Us 132
Disclaimer 132
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Regeneron Pharma Acquires Rights To Two Antibodies From Sanofi 16
Decibel Therapeutics Raises USD55 Million in Series C Venture Financing 17
TRC Capital To Acquire 1.06% Stake In Regeneron Pharma For US$161 Million 19
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 20
Replimune Enters into Co-Development Agreement with Regeneron Pharma 22
Regeneron Pharma Enters into Agreement with Alnylam Pharma 23
Regeneron Pharma and ISA Pharma Enter into Partnership 24
Regeneron Pharma Enters into Co-Development Agreement with Decibel Therapeutics 25
Aimmune Therapeutics Enters into Agreement with Regeneron Ireland and Sanofi Biotech 26
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority for Infectious Diseases 27
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 28
Inovio Pharma and Regeneron Pharma Enter into Agreement 29
Indivumed Enters into Agreement with Regeneron Pharma 30
Regeneron Pharma Enters into Co-Development Agreement with Ocular Therapeutix 31
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 33
Regeneron Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 34
Bayer Enters into Co-Development Agreement with Regeneron Pharma 35
Regeneron Pharma Enters into Agreement with Mitsubishi Tanabe Pharma 36
Regeneron Pharma Enters into Research Agreement with Icahn School of Medicine at Mount Sinai 37
Regeneron Pharma Enters into Development Agreement with BARDA 38
Regeneron Pharma Amends Co-Development Agreement with Sanofi 39
Regeneron Pharma Amends Co-Development Agreement with Sanofi 41
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 42
Regeneron And Bayer Enter Into Co-Development Agreement For Eylea Combination Treatment 43
Regeneron Pharma And Bayer Yakuhin Enter Into Co-Promotion Agreement With Santen Pharma For Eylea 44
Kiniksa Pharma Enters into Licensing Agreement with Regeneron 46
Neovii Pharmaceuticals Enters into Licenses Agreement with Regeneron 47
Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 48
Regeneron Pharma Enters into Licensing Agreement with MedImmune 50
Regeneron Pharma Enters into Licensing Agreement with Adicet Bio 51
Regeneron Pharma Enters into Licensing Agreement with ERS Genomics 52
Regeneron Pharmaceuticals Inc, Key Competitors 53
Regeneron Pharmaceuticals Inc, Key Employees 54
Regeneron Pharmaceuticals Inc, Other Locations 56
Regeneron Pharmaceuticals Inc, Subsidiaries 56
List of Figures
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Regeneron Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 12